Cabazitaxel (JEVTANA) Is a National Comprehensive Cancer Network® (NCCN®) Designated Category 1 2nd-Line Therapy Option in mCRPC After Docetaxel and a Novel Hormonal Therapy1

Taxane Chemical Structure2

The Structure of JEVTANA and Its Pharmacokinetics at the Cellular Level2,3

In vitro, JEVTANA showed poor binding affinity for P-glycoprotein, a broad-spectrum multidrug efflux pump, as well as antitumor activity against docetaxel-refractory tumor cells.

Moreover, JEVTANA is not a substrate of:

  • Efflux pumps MRP1 (multidrug-resistance protein 1), MRP2 (multidrug-resistance protein 2), BCRP (breast cancer resistance protein)
  • Solute carrier (SLC) transporters OCT1 (organic cation transporter), OATP1B1 or OATP1B3 (organic anion transporting polypeptides)

mCRPC=metastatic castration-resistant prostate cancer.

See how JEVTANA works